Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Was This Driver Simply Having Some good times Or Behaving Like An Ass? - 2The most effective method to Quick Track Your Outcome in Advanced Showcasing with a Web-based Degree
- 3The most effective method to Help a Friend or family member Determined to have Cellular breakdown in the lungs
- 4David Duchovny's new thriller has him stripping down at 65. But its chilling premise hits close to home.
- 5Iran-backed militias reassert power in Iraq, proving the Islamic axis is still standing
- James Webb Space Telescope finds strongest evidence yet for atmosphere around rocky exoplanet: 'It's really like a wet lava ball'
- 4 DSLR Cameras for Amateurs in 2024
- San Francisco sues 10 companies that make ultraprocessed food
- Novartis to build manufacturing hub in North Carolina, creating 700 jobs
- 6 Popular Men's Aromas On the planet
- Manual for 6 Busssiness Class Flights
- UN chief calls on Yemen's Houthi rebels to free all UN detainees
- Hypothermia claims newborn in Gaza and more babies are at risk, doctor says
- 5 Home EV Chargers for Proficient and Solid Charging
